NCT06573593

Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study

Efficacy and Safety of JAK Inhibitors in Patients With Alopecia Areata: a Single-center, Real-world Study

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 150 (estimated)
• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
• Sex: All
• Age: 2 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing. To provide evidence about effectiveness and safety of different JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib in real-world settings and describe baseline disease characteristics and patients profiles that are considered good candidates for JAKi in the daily practice. Furthermore, we intended to investigate the efficacy and safety of JAK Inhibitors in patients With AA, as well as to provide clinical evidence for the clinicians and patients when they formulate individualized treatment plans.

Conditions

• Alopecia Areata
• Janus Kinase Inhibitors

Interventions

Type	Name	Description
DRUG	Tofacitinib	In the real-world settings, patients with AA treated with tofacitinib.
DRUG	Baricitinib	In the real-world settings, patients with AA treated with Baricitinib.
DRUG	Ruxolitinib	In the real-world settings, patients with AA treated with Ruxolitinib.
DRUG	Upadacitinib	In the real-world settings, patients with AA treated with Upadacitinib.
DRUG	Abrocitinib	In the real-world settings, patients with AA treated with Abrocitinib.
DRUG	Ritlecitinib	In the real-world settings, patients with AA treated with Ritlecitinib.

Timeline

• Start date: 2024-07-29
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2024-08-27
• Last updated: 2024-08-27

Locations

1 site across 1 country: China